Polyvalent AIDS vaccines.
A major hurdle in the development of a global HIV-1 vaccine is viral diversity. For close to three decades, HIV vaccine development has focused on either the induction of T cell immune responses or antibody responses, and only rarely on both components. After the failure of the STEP trial, the scientific community concluded that a T cell-based vaccine would likely not be protective if the T cell immune responses were elicited against only a few dominant epitopes. Similarly, for vaccines focusing on antibody responses, one of the main criticisms after VaxGen's failed Phase III trials was on the limited antigen breadth included in the two formulations used. The successes of polyvalent vaccine approaches against other antigenically variable pathogens encourage implementation of the same approach for the design of HIV-1 vaccines. A review of the existing HIV-1 vaccination approaches based on the polyvalent principle is included here to provide a historical perspective for the current effort of developing a polyvalent HIV-1 vaccine. Results summarized in this review provide a clear indication that the polyvalent approach is a viable one for the future development of an effective HIV vaccine.
Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. shan.lu@umassmed.edu
Shan
S
Lu
Jill M
JM
Grimes Serrano
Shixia
S
Wang
D016915:AIDS Vaccines / Q000276:immunology*; D006801:Humans; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology*
D016915:AIDS Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit